On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview - RNA interference as an antiviral tool
- RNA interference pathway
- RNA interference methods
- Antisense vs. RNAi
- Inhibition of HIV-1 by RNAi
- Virus inhibition by RNAi - RNA viruses
- Virus inhibition by RNAi - DNA viruses
- Coxsackievirus B3 (CVB-3)
- Picornavirus replication
- Dilatated cardiomyopathy (DCM)
- Overview - design of efficient siRNAs
- siRNAs targeting the Coxsackievirus 5' UTR
- siRNAs against 5' UTR of CVB-3 have no effect
- Screening for efficient siRNAs against TRPV1
- What makes an efficient siRNA?
- Efficient siRNA - strand bias or target structure?
- Accessible nucleotides at 3' or 5' end of target site
- Activation of seemingly inactive siRNA
- Folding of artificial siRNA targets
- siRNA silencing and local stability - correlation
- Model for determinants of siRNA efficiency
- Overview - inhibition of coxsackievirus replication
- Targeting the viral RdRP
- Coxsackievirus replication in cell culture
- Cell viability assay with siRdRP 1-4
- Inhibition of virus replication by siRNA
- Inhibition of Coxsackievirus B3 by siRNA
- CVB-3 inhibition in vivo
- Overview - strand selectivity of virus silencing
- Replication cycle of picornaviruses
- Selective strand silencing
- Strand-selectivity of siRdRP
- Design of siRNAs targeting the RdRP (-)-strand
- Strand-specificity of silencing
- Strand specific siRNAs
- Strand-inactivation by incorporation of LNA
- siRNA vs. siLNA
- Overview - SiDEx
- Silencing of RdRP by shRNA expression plasmid
- Long-term silencing generates escape mutants
- Silencing of mutated RdRP
- SiRNA double expression vector (SiDEx)
- SiDEx silences two target sites
- SiDEx silences wt and mutated RdRP
- SiDEx - silencing of mutated RdRP
- Silencing of mutated target site 4
- Overview - silencing of CAR
- Coxsackievirus-adenovirus-receptor (CAR)
- Screening for efficient siRNAs targeting CAR
- Efficiency of CAR-siRNAs
- Duration of silencing
- Inhibition of virus propagation by CAR-siRNA
- SiDEx vector against two target sites of CVB-3
- Summary
- Acknowledgement
Topics Covered
- Coxsackievirus B3
- Design of efficient antiviral siRNAs
- Plaque reduction assays
- Virus escape
- siRNA double expression vectors (SiDEx)
- Strand selectivity of virus silencing
- Silencing of the host receptor (Coxsackievirus-adenovirus receptor)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kurreck, J. (2007, October 1). RNAi and viral heart infections [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/FJIU3524.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jens Kurreck has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.